Format

Send to

Choose Destination
J Neurovirol. 2006 Oct;12(5):403-6.

Valproic acid does not affect markers of human immunodeficiency virus disease progression.

Author information

1
Department of Neurosciences, University of California, San Diego, California, USA. bances@ucsd.edu

Abstract

Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.

PMID:
17065134
DOI:
10.1080/13550280600981695
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center